Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson’s disease in the UK and Germany

References

• de Lau LML, Breteler Monique MB. Epidemiology of Parkinson’s disease. Lancet Neurol 2006;5:525-35
   PubMed Web of Science ®Google Scholar
• von Campenhausen L, Bornschein B, Wick R, et al. Revalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol 2005;15:473-90
   PubMed Web of Science ®Google Scholar
• Poewe WH, Lees AJ, Stern GM. Low-dose L-dopa therapy in Parkinson’s disease: a 6-year follow-up study. Neurology 1986;36:1528-30
   PubMed Web of Science ®Google Scholar
• Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson’s disease A community-based study. Oxf J Med Brain 2000;123:2297-305
   PubMed Web of Science ®Google Scholar
• Hilker R, Antonini A, Odin P. What is the best treatment for fluctuating Parkinson’s disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus? J Neural Transm 2011;118:907-14
   PubMed Web of Science ®Google Scholar
• Deuschl G, Schade-Brittinger C, Krack P. A randomized trial of deep-brain stimulation for Parkinson’s Disease. N Engl J Med 2006;355:896-908
   PubMed Web of Science ®Google Scholar
• Eggington S, Valldeoriola F, Chaudhuri KR, et al. The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson’s disease. J Neurol 2014;261:106-16
   PubMed Web of Science ®Google Scholar
• Dams J, Siebert U, Bornschein B, et al. Cost-effectiveness of deep brain stimulation in patients with Parkinson’s disease. Mov Disord 2013;28:763-71
   PubMed Web of Science ®Google Scholar
• Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinson’s disease: a cost-effectiveness analysis. Neurology 2001;57:663
   PubMed Web of Science ®Google Scholar
• Lowin J, Bergman A, Chaudhuri KR, et al. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson’s disease in the UK. J Med Econ 2011;14:584-93
   PubMedGoogle Scholar
• Valldeoriola F. Cost and efficacy of therapies for advanced Parkinson’s disease. Barcelona, Spain: Institut de Neurociències, Hospital Clínic, Universitat de Barcelona, 2011
   Google Scholar
• Willis M, Persson U, Zoellner Y, et al. Reducing uncertainty in value-based pricing using evidence development agreements. The case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa) in Sweden. Appl Health Econ Health Policy 2010;8:1-10
   PubMedGoogle Scholar
• Findley LJ, Lees A, Apajasalo M, et al. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson’s disease patients with wearing-off. Curr Med Res Opin 2005;21:1005-14
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisals. 2008. NICE, UK. http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed April 13, 2012
   Google Scholar
• IQWIG. Kosten und Nutzen in der Medizin Die Analyse von ‘Effizienzgrenzen‘: Allgemeine Methoden zur Bewertung von Verhältnissen zwischen Nutzen und Kosten; Cologne, 2009
   Google Scholar
• Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decsn Mak 1993;13:322-38
   PubMed Web of Science ®Google Scholar
• Keeler E. Decision trees and Markov models in cost-effectiveness research. In: Sloan FA, ed. Valuing Health Care. Cambridge: Cambridge University Press, 1996. p. 185-205
   Google Scholar
• García Ruiz PJ, Ignacio AS, Pensado BA, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicenter study. Mov Disord 2008;23:1130-6
   PubMed Web of Science ®Google Scholar
• Pollak P, Champay AS, Gaio JM, et al. Subcutaneous administration of apomorphine in motor fluctuations in Parkinson’s disease. Rev Neurol (Paris) 1990;146:116-22
   PubMed Web of Science ®Google Scholar
• Gancher ST, Nutt JG, Woodward WR. Apomorphine infusional therapy in Parkinson’s disease: clinical utility and lack of tolerance. Mov Disord 1995;10:37-43
   PubMed Web of Science ®Google Scholar
• Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson’s disease: a prospective study using single-dose challenges. Mov Disord 2005;20:151-7
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Critchley P, Abbott RJ, et al. Subcutaneous apomorphine for on-off oscillations in Parkinson’s disease. Lancet 1988;2:1260
   PubMed Web of Science ®Google Scholar
• Stocchi F, Bramante L, Monge A, et al. Apomorphine and lisuride infusion. A comparative long-term study. Adv Neurol 1993;60:653-5
   PubMedGoogle Scholar
• De Gaspari D, Siri C, Landi A, et al. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 2006;77:450-3
   PubMed Web of Science ®Google Scholar
• Eggert K, Schrader C, Hahn M, et al. Continuous jejunal levodopa infusion in patients with advanced Parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008;31:151-66
   PubMed Web of Science ®Google Scholar
• Antonini A, Isaias IU, Canesi M, et al. Duodenal levodopa infusion for advanced Parkinson’s disease: 12-month treatment outcome. Mov Disord 2007;22:1145-9
   PubMed Web of Science ®Google Scholar
• Raudino F, Garavaglia P, Pianezzola C, et al. Long-term experience with continuous duodental levodopa-carbidopa infution (Duodopa): report of six patients. Neurol Sci 2009;30:85-6
   PubMed Web of Science ®Google Scholar
• Lisitchkina H, Ide J, Zutter D. Therapieerfahrung mit der pumpengesteuerten en-teralen Infusion eines Levodopa/Carbidopa-Gels bei fortgeschrittenem Morbus Parkinson. Schweizer Archiv für Neurologie und Psychiatrie 2011;162:122-6
   Google Scholar
• Palmer CS, Schmier JK, Snyder E, et al. Patient preferences and utilities for ‘off-time’ outcomes in the treatment of Parkinson’s disease. Qual Life Res 2000;9:819-27
   PubMed Web of Science ®Google Scholar
• Davey P, Rajan N, Lees M, et al. Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson’s disease: a decision-analytic model. Value Health 2001;4:308-15
   PubMedGoogle Scholar
• Palmer CS, Nuijten MJ, Schmier JK, et al. Cost effectiveness of treatment of Parkinson’s disease with entacapone in the United States. Pharmacoeconomics 2002;20:617-28
   PubMed Web of Science ®Google Scholar
• Ceballos-Baumann A. Continuous subcutaneous infusion therapy with the Apomorphine Pump. Akt Neurol 2011;38:17-26
   Google Scholar
• Dams J, Bornschein B, Reese JP, et al. Modelling the cost effectiveness of treatments for Parkinson’s disease: A Methodological Review. Pharmacoeconomics 2011;29:1025-49
   PubMed Web of Science ®Google Scholar
• Findley LJ, Wood E, Lowin J, et al. The economic burden of advanced Parkinson’s disease: an analysis of a UK patient dataset. J Med Econ 2011;14:130-9
   PubMedGoogle Scholar
• Pereira E, Nandi D, Aziz T. Deep brain stimulation: an underused panacea? ACNR 2008;8:4
   Google Scholar
• Gold M, Siegel J, Russel L, et al, eds. Cost-effectiveness in health and medicine. Philadelphi, PA: WB Staunders, 1996
   Google Scholar
• Kristiansen IS, Bingefors C, Nyholm D, et al. The cost-effectiveness of continuous duodenal delivery of levodopa (Duodopa) in patients with severe Parkinsons disease [abstract]. Mov Disord 2005;20(10 Suppl):80
   Google Scholar
• Lundqvist C. Continuous levodopa for advanced Parkinson’s disease. Neuropsychiatr Dis Treat 2007;3:335-48
   PubMedGoogle Scholar
• Dodel R, Eggert KM, Singer MS, et al. Costs of drug treatment in Parkinsons disease. Mov Disord 1998;13:249-54
   PubMed Web of Science ®Google Scholar
• Meissner W, Trottenberg T, Klaffke S, et al. Apomorphinterapie versus tiefe Hirnstimulation. Nervenarzt 2001;72:924-7
   PubMedGoogle Scholar
• Zhao YJ, Wee HL, Chan YH, et al. Progression of Parkinson’s disease as evaluated by Hoehn and Yahr stage transition times. Mov Disord 2010;25:710-6
   PubMed Web of Science ®Google Scholar
• Reddy P, Martinez-Martin P, Todorova A, et al. The EuroInf Study: a multi-centre European comparative study of apomorphine versus intrajejunal levodopa infusion in a real life cohort of Parkinson’s patients [abstract]. Mov Disord 2013;28(1 Suppl):596
   Google Scholar
• The World Standard Drug Database. online database from SafeScript Limited, London. http://admin.safescript.com/. Accessed April 2, 2014
   Google Scholar
• LAUER Taxe [LAUER FISCHER GmbH web site]. online database from Lauer Fischer Germany. www2.lauer-fischer.de. Accessed April 12, 2014
   Google Scholar
• Personal Social Services Research Unit [The University of Kent]. Unit costs of health and social care 2011. Personal Social Services Research Unit PSSRU, Kent. http://www.pssru.ac.uk/pdf/uc/uc2011/uc2011.pdf. Accessed October 4, 2012
   Google Scholar
• EBM – einheitlicher Bewertungsmaβstab. Kassenaerztliche Bundesvereinigung. 2014. Kassenärtzliche Bubdesvereinigung, Berlin. http://www.kbv.de. Accessed April 16, 2014
   Google Scholar
• Farkouh RA, Wilson MR, Tarrants ML, et al. Cost-effectiveness of Rasagiline compared with first-line early Parkinson disease therapies. Am J Pharm Benefits 2012;3:99-107
   Google Scholar